Phase 2 Brain Cancer Trial, Recruiting NCT06297512 Sponsor: Iacopo Sardi Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT06297512
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You (or your child) have been diagnosed with a specific type of brain tumor (a form of glioblastoma or related high-grade brain tumor) confirmed by laboratory testing, including cases where the tumor has spread or affects multiple areas of the brain
  • This is a first-time diagnosis and the tumor has not yet been treated with chemotherapy or radiation — surgery alone is acceptable
  • The patient is between 3 and 30 years old (male or female)
  • The patient is expected to live for at least 12 months
  • The patient is generally functioning well in daily life, scoring 80% or above on a standard health performance scale (confirm with trial site)
  • Blood counts are within acceptable levels — enough white blood cells, red blood cells, and platelets
  • The liver is functioning adequately, based on standard blood test results
  • The kidneys are functioning adequately, based on standard blood test results
  • The patient, their parents, or legal guardians are able to sign a written consent form agreeing to take part
  • The patient is willing and able to follow the trial's treatment plan and schedule

Who may not be able to join:

  • The patient has another serious illness or condition that would make the trial treatment unsafe — for example, severe heart disease, severe cerebral palsy, or severe congenital conditions
  • The patient is already receiving a first course of chemotherapy at the time of joining the trial
  • The patient is currently taking part in another research study
  • The patient is pregnant or breastfeeding
  • The patient is not using an appropriate method of contraception (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Iacopo Sardi, Meyer Children's Hospital IRCCS

Phone: 0555662631

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Iacopo Sardi
Registry
ClinicalTrials.gov
Start date
9 December 2022
Est. completion
9 November 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Evaluation prolonged Dox; Percentage of Withdrawal from the study rate; Percentage of SAEs; Mortality rate; Early discontinuation of dox treatment rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov